Browse the corpus

Linezolid is a synthetic oxazolidinone antimicrobial drug indicated for gram-positive infections and approved for the treatment of bacterial pneumonia, skin and skin structure infections, and vancomycin-resistant enterococcal (VRE) infections, including infections complicated by bacteremia. Linezolid does not have approval for the treatment of gram-negative infections, catheter-related bloodstream infections, or catheter site infections. The primary mechanism of linezolid is an alternative to vancomycin in inpatient settings. This activity covers linezolid so that interprofessional team members can recognize its indications, coverage, contraindications, and adverse event profile to optimally manage patients with infectious diseases and exercise appropriate antimicrobial stewardship. Empowering healthcare professionals with enhanced proficiency is pivotal in advancing patient care standards, particularly in the dynamic landscape of bacterial infection management, where pathogens like methicillin-resistant Staphylococcus aureus (MRSA) present formidable challenges. Participating clinicians are equipped with the skills to effectively integrate linezolid into clinical practice, ensuring optimal treatment outcomes when treating bacterial infections. Objectives: Identify the mechanism of action for linezolid to apply knowledge of the spectrum of activity against pathogens. Determine the indications for initiating linezolid therapy by considering clinical presentation, medication interactions, and risk factors. Evaluate bacterial infections with infectious disease consultation to optimize the use of linezolid in patient treatment plans. Implement effective collaboration among interprofessional team members to improve treatment efficacy from linezolid therapy. Access free multiple choice questions on this topic.

Toxicity is infrequent, and no antidote for linezolid is currently available. Symptomatic and supportive treatment is recommended for managing mild to severe toxicity. For severe neutropenia, administer colony-stimulating factors such as filgrastim or sargramostim. Filgrastim is dosed at 5 mcg/kg/day subcutaneous (SQ) or IV over 15 to 30 minutes, or sargramostim at 250 mcg/m2/day IV over 4 hours. Transfusion of platelets, packed red cells, or both may be necessary for patients with severe thrombocytopenia, anemia, or hemorrhage. For seizures, administer IV benzodiazepines; barbiturates or propofol may be an option if seizures persist or recur. Airway management may be necessary for patients with severe seizures. The primary treatment for serotonin syndrome is sedation with IV benzodiazepines and cooling measures (cyproheptadine is an option for milder cases). Start with an initial dose of 12 mg of cyproheptadine, followed by 2 mg every 2 hours if symptoms persist. When stability is attained, switch to a maintenance dose of 8 mg every 6 hours. Ensure that the daily dose for adults does not surpass 0.5 mg/kg/day.[38] Activated charcoal is a consideration in patients with a recent overdose of linezolid tablets and co-ingested potentially dangerous medications, eg, tricyclic antidepressants. Monitoring is necessary for vital signs and liver enzymes in symptomatic patients. Additionally, monitor serial CBC with differential and platelet count. Reports exist of myelosuppression, including anemia, pancytopenia, leukopenia, and thrombocytopenia in patients receiving linezolid. Monitoring serum electrolyte status is indicated for patients with significant diarrhea and vomiting.

The healthcare team should work together to ensure the patient receives linezolid correctly and is monitored for adverse drug reactions. Educate the patient on the signs of significant adverse drug reactions such as wheezing, chest tightness, seizures, swelling of the face, lips, tongue, or throat, and severe diarrhea. Encourage the patient to consult the treating clinician for questions about linezolid treatment. To prevent the inappropriate clinical use of linezolid, most hospitals have a committee that includes a pharmacist and an infectious disease expert who should authorize the prescription. A study evaluated the impact of interventions by an antimicrobial stewardship team (AST) involving the pharmacy, microbiology, and infectious diseases departments on linezolid utilization. Using defined daily doses (DDD) per 1,000 inhabitants per day as a metric, the study found that 60% of linezolid prescriptions were considered appropriate. Inappropriate treatments were modified or discontinued in 62% and 38% of cases. The mean duration of linezolid treatment was 8 days, below the national average. Interprofessional teams developed a consensual approach for treating ventilator-acquired pneumonia. Importantly, the mean DDD per 1,000 inhabitants per day showed a gradual and favorable reduction throughout the study, highlighting the positive impact of the team's actions in optimizing linezolid use. IDSA also suggests that clinicians coordinate for effective antimicrobial stewardship.[39][40][39]